• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2026
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • PRODUCT LIBRARY

Why Didn’t Globus Medical’s Stock Rise After Their Excellent Financial Results?

February 21, 2025 By SPINEMarketGroup

Globus Medical’s results published yesterday were excellent, with a 6.6% increase in fourth-quarter sales for 2024 and an impressive 60.6% annual growth in sales. However, despite these solid numbers, the company’s stock did not experience the expected rise and dropped slightly.

Full Year 2024:

  • Worldwide net sales were $2,519.4 million, an increase of 60.6% on an as-reported basis and an increase of 61.1% on a constant currency basis.
  • GAAP net income for the year was $103.0 million
  • GAAP diluted EPS was $0.75 and non-GAAP diluted EPS was $3.04
  • Non-GAAP adjusted EBITDA was $735.0 million, or 29.2% of net sales.

So What Happened Yesterday?

While these numbers are undeniably strong, the market response was not in line with expectations. The stock opened at $83.61, and closed at $84.12, but fell to $83.83 in after-hours trading following the publication of these figures.

What’s Behind This Market Reaction?

One possible explanation is that investors had already anticipated these positive results, incorporating them into the stock price beforehand. Sometimes, when a company releases good results that were already expected, the stock price doesn’t rise significantly because investors have already adjusted their expectations based on those numbers.

Additionally, the recent $250 million acquisition of Nevro Corp. may be causing caution in the market. While the acquisition could be a long-term strategy, the integration of the company and the associated costs could create short-term uncertainty. This, along with potential financial risks from the purchase, could be affecting investor sentiment and, in turn, the stock price.

Outlook for the Coming Months

Despite these short-term setbacks, Globus Medical’s strong financial results and its expansion through the acquisition of Nevro present a positive outlook for the future. If the company can overcome the challenges related to Nevro’s integration and continue reporting good numbers, the stock may see significant growth in the coming months.

Thoughts

As we have said before, we trust in the leadership of David Paul, Dan Scavilla, and their entire team. Globus has focus, talent, and determination to succeed and win. While we are not in the business of stock trading or advising on this matter, we will simply say that we are holding onto our Globus shares because we believe they will soon bring us great rewards. As some might say: HOLD or HODL (“Hold On for Dear Life”)!

###

Related Posts:

  • Globus Medical Reports Fourth Quarter and Full Year…
  • Globus Medical Reports Fourth Quarter and Full Year…
  • Globus Medical Reports Fourth Quarter and Full Year…

Filed Under: NEWS Tagged With: 2025

Primary Sidebar

PLATINUM SPONSORS

EXALTA 2LOGO-min
GLOBAL biomedica
NORMED newLOGO-min
GENESYS SPINE
SPINEGUARD2025
Dymicron 2
GSMEDICAL2025
spinewaygroup
RUTHLESS SPINE
RUDISHAUER
NGMEDICAL
LfC
ispine
CENTINEL SPINE
TSUNAMI MEDICAL
syntropiq logo
A-SPINE
L&Kmodelo log

POPULAR POST LAST 90 DAYS

  • Globus Medical and Synaptive: Why the Rumors Deserve…
  • What Globus Medical Really Bought With Higgs Boson Health
  • BROCHURES
  • Globus Medical Announces Acquisition of Higgs Boson…
  • Neck and Neck: Is Globus Finally About to Overtake…
  • Who Runs DePuy Synthes? The CEO Fight That Killed…
  • Globus Medical to Showcase SCRIPT™ Patient-Specific…
  • J&J’s $21B DePuy Synthes Bet Could End in…
  • Federal Circuit Backs Globus Medical in Spinal…
  • Centinel Spine Files for NYSE IPO After 42% Jump in…
  • COMPANIES
  • Do Spine Companies Really Need So Many Implants?…
  • Record Earnings, Discount Valuation: What Globus…
  • DePuy Synthes for Sale: Who Could Actually Buy the…
  • Globus Medical Reports Third Quarter 2026 Results…
  • New CFO, New AI Chief and a Patent Fight: What Is…
  • (UPDATED 2026) More Than 100 Options, No Single…
  • CD HORIZON® SOLERA™ System
  • 3D-Printed Cages Are Everywhere. Has the Technology…
  • Top Expandable Cages of 2025: Which Lumbar Implants…
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • Globus Medical Acquires Synaptive Medical,…
  • SYMPHONY Occipito-Cervico-Thoracic (OCT) System
  • What Is a Spine Hub, and Why Did Avesi Invest in New…
  • Whatever Happened to the Translational Cervical…
  • Forty Cervical Discs, One 3% Market: The Fight to…
  • Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
  • FDA clears Solco’s Blue Dolphin cage for minimally…
  • Thinking About a Spine Robot? Your 2026 Guide to the…
  • Carlsmed, Inc. Files Patent Infringement Lawsuit…
  • LAST 5 VIDEOS PUBLISHED

    1. GS Medical: QUASAR™ Stand-Alone ACIF
    2. SI-BONE: iFuse Granite Onyx™
    3. NovaSpine: DIVA Cervical
    4. Xenix Medical: Riva Modular Fixation System
    5. Spinal Elements: Overwatch® PCF

    Footer

    Contact us:

    spinemarketgroup@gmail.com info@thespinemarketgroup.com

    • LinkedIn
    • Twitter
    • YouTube

    PRIVACY POLICY

    • Legal
    • PRODUCT LIBRARY

    Copyright © 2026 · SPINEMarketGroup